Repligen Corp (RGEN) bonds
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)
Close on Nov 18, 2026Market cap $11.04BP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Repligen reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Repligen's 10-Q for the period ended Sep 30, 2026
| Issue | Coupon | Matures | Amount issued | Carrying value |
|---|---|---|---|---|
| 1.00% Convertible Senior Notes due 2028 Convertible at $203 a share | 1.00% | Dec 15, 2028 | $600.00M | $555.60M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?